National Research (NASDAQ:NRC – Get Free Report) and Phreesia (NYSE:PHR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares National Research and Phreesia”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| National Research | $140.00 million | 3.43 | $11.60 million | $0.25 | 84.37 |
| Phreesia | $507.79 million | 1.35 | $2.31 million | $0.17 | 64.95 |
National Research has higher earnings, but lower revenue than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
National Research has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and target prices for National Research and Phreesia, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| National Research | 1 | 1 | 1 | 0 | 2.00 |
| Phreesia | 1 | 10 | 8 | 0 | 2.37 |
National Research presently has a consensus price target of $26.00, suggesting a potential upside of 23.26%. Phreesia has a consensus price target of $14.07, suggesting a potential upside of 27.39%. Given Phreesia’s stronger consensus rating and higher possible upside, analysts plainly believe Phreesia is more favorable than National Research.
Profitability
This table compares National Research and Phreesia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| National Research | 4.18% | 164.26% | 14.67% |
| Phreesia | 2.06% | 5.22% | 3.02% |
Insider & Institutional Ownership
47.3% of National Research shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 5.2% of Phreesia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
National Research beats Phreesia on 8 of the 14 factors compared between the two stocks.
About National Research
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
About Phreesia
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.
